Related Experiment Video

Updated: May 13, 2026

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

Myocardial no-reflow treatment

Olivier Muller1, Catalina Trana, Eric Eeckhout

  • 1Cardiology department, Centre Hospitalier Universitaire Vaudois, Rue du Bugnon 21, Lausanne, Switzerland.

Current Vascular Pharmacology
|March 20, 2013
PubMed

Insights

The no-reflow phenomenon, a complication of percutaneous coronary intervention (PCI), can be managed through pharmacological agents or mechanical strategies. This review explores current literature on treating no-reflow, despite limited clinical endpoint data.

Area of Science:

  • Cardiology
  • Interventional Cardiology

Background:

  • The no-reflow phenomenon is a common complication following percutaneous coronary intervention (PCI), particularly in myocardial infarction.
  • It can also occur in stable angina patients undergoing specific PCI techniques like rotational ablation or saphenous vein graft angioplasty.

Purpose of the Study:

  • To review and summarize current pharmacological and mechanical treatment strategies for the no-reflow phenomenon.
  • To present a treatment algorithm for no-reflow based on existing literature.

Main Methods:

  • Literature review of pharmacological agents (adenosine, nitroprusside, verapamil, nicorandil, dipyridamole, epinephrine, cyclosporine).
  • Literature review of mechanical strategies (intra-aortic balloon pumping, postconditioning).

Main Results:

  • Several pharmacological compounds have been assessed for no-reflow treatment.
  • Limited mechanical strategies like intra-aortic balloon pumping and postconditioning have been examined.
  • No studies demonstrated a definitive beneficial effect on clinical endpoints for any treatment.

Conclusions:

  • Current literature provides insights into pharmacological and mechanical approaches for no-reflow.
  • An algorithm for no-reflow management is proposed, acknowledging the lack of clinical endpoint evidence.
  • Further research is needed to establish effective treatments with proven clinical benefits.

More Related Videos

Myocardial Infarction and Functional Outcome Assessment in Pigs12:03

Myocardial Infarction and Functional Outcome Assessment in Pigs

Published on: April 25, 2014

Related Concept Videos

Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Cardiopulmonary Resuscitation IV: Pharmacological Management01:25

Cardiopulmonary Resuscitation IV: Pharmacological Management

Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...